trending Market Intelligence /marketintelligence/en/news-insights/trending/X5GQu1xa06ZabJg4bBV71g2 content esgSubNav
In This List

SK Capital acquires Perrigo's active pharmaceutical ingredients business

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


SK Capital acquires Perrigo's active pharmaceutical ingredients business

Perrigo Co. plc's active pharmaceutical ingredients business was renamed to Wavelength Pharmaceuticals after U.S. private investment firm SK Capital completed the acquisition.

Wavelength produces generic active pharmaceutical ingredients, with primary operations in Israel and supporting functions in the U.S. and India.

Apollo Global Management and its affiliates along with MidCap Financial provided debt financing for the transaction. RBC Capital Markets LLC and Rothschild acted as SK Capital's joint advisers.